PCN81 Cost-Effectiveness Analysis of Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous CELL Carcinoma in Patients Whose Tumor Expressed Programmed Death-Ligand 1 at Combined Positive Score ≥1 in France
Dec 1, 2020, 00:00
10.1016/j.jval.2020.08.218
https://www.valueinhealthjournal.com/article/S1098-3015(20)32474-8/fulltext
Title :
PCN81 Cost-Effectiveness Analysis of Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous CELL Carcinoma in Patients Whose Tumor Expressed Programmed Death-Ligand 1 at Combined Positive Score ≥1 in France
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(20)32474-8&doi=10.1016/j.jval.2020.08.218
First page :
Section Title :
Open access? :
No
Section Order :
10168